engages in the development, manufacture, and marketing of products that use radiofrequency energy to treat patients with cancerous or benign tumors.
It offers radiofrequency ablation systems for treating cancerous tumors, as well as percutaneous vascular ports and specialty access catheters (SAC). The company’s radiofrequency ablation (RFA) system consists of disposable devices and generators.
RITA’s RFA system delivers radiofrequency energy to raise the temperature of affected cells above 45 to 50°C, causing cellular death.
Its vascular access ports are implantable devices utilized for the central venous administration of various medical therapies, and for blood sampling and diagnostic purposes.
In addition, the company manufactures and markets SAC products, including hemodialysis catheters, central venous catheters, needle infusion sets, peripherally inserted central venous catheters, and other accessories used in vascular procedures.
RITA’s customers primarily include surgical oncologists, hepatobiliary surgeons, liver transplant surgeons, laparoscopists, and interventional radiologists, as well as colorectal surgeons, radiation oncologists, and medical oncologists.
It markets products through a direct sales force and distributors in the United States, and through distribution partners in Europe and Asia.
The company was founded in 1994 and is headquartered in Fremont, California.
